Sign in
Taking peoplePhase 3

Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder

Key facts

Who runs it
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
495 people, planned
Started
17 Apr 2023
Planned end
1 Jun 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Shugan Jieyu Capsules
  • Shugan Jieyu Capsules Placebo
Record updated
18 December 2024

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Primary diagnosis of generalized anxiety disorder (GAD) as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as confirmed by the MINI at Screening, The duration of illness must be ≥ 6 months;
  • Age 18-65 years old;
  • Hamilton Anxiety Rating Scale (HAM-A) Total Score of ≥ 14 at both Screening and Baseline,Anxious Mood (item 1) score ≥2;
  • Clinical Global Impression of Severity Scale (CGI-S) score of ≥ 3 at both Screening and Baseline
  • The TCM syndrome is liver Qi stagnation and spleen deficiency syndrome

Who cannot take part

  • Diagnosed with a psychiatric disorder other than GAD that meets DSM-5 criteria within 6 months prior to screening;
  • Alcohol or drug abuse or dependence in the 6 months prior to screening, or urine positive for multiple drugs combined at screening
  • Hamilton Depression Rating Scale (HAMD-17) Total Score of > 17 at Screening or Baseline,or Depressive Mood (item 1) score ≥2;
  • Patients with Severe Insomnia

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Generalized anxiety disorder

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized double-blind placebo-controlled phase 3 clinical trial to further validate the effectiveness and safety of Shugan Jieyu Capsules in treating generalized anxiety disorder.

The 2 groups in the trial

  • Experimental: Shugan Jieyu CapsulesTreatment being tested

    Participants received Shugan Jieyu Capsules 4 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.

    Treatment: Shugan Jieyu Capsules

  • Experimental: Shugan Jieyu Capsules PlacepoPlacebo, for comparison

    Participants received Shugan Jieyu Capsules Placebo 4 capsules,BID,once in the morning and once in the evening, at an interval of more than 8 hours, for up tp 12 weeks.

    Treatment: Shugan Jieyu Capsules Placebo

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-center, Randomized, Double-Blind Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder
Criteria questions
Built from NCT05772104, who can take part
Record updated
18 December 2024